University of Wisconsin Carbone Cancer Center | Strategic Alliance Partners

May 28, 2021

Nataliya V. Uboha, MD, PhD, zeros in on the developments with ADCs and monoclonal antibodies in gastric cancer and recent changes in pancreatic cancer as key takeaways from the event.

May 11, 2021

Monica A. Patel, MD, discusses factors that determine whether a patient with hepatocellular carcinoma is a good candidate to receive a combination of atezolizumab and bevacizumab.

May 05, 2021

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.

February 24, 2021

Natalie S. Callander, MD, discusses the intriguing approaches in both the frontline and relapsed/refractory settings, including trials with antibody-drug conjugates.

February 22, 2021

Timothy M. Schmidt, MD, discusses the safety and efficacy of teclistamab in patients with multiple myeloma.

February 19, 2021

Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.

January 28, 2021

Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.

January 22, 2021

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

November 04, 2020

Unprecedented treatment advances have been made during the last decade for patients with advanced melanoma.

November 03, 2020

Kari B. Wisinski, MD, discusses the evolving roles of immunotherapy, ADCs, and PARP inhibitors in triple negative breast cancer.

October 22, 2020

Parameswaran Hari, MD, MRCP, discusses key data that has read out in relapsed/refractory multiple myeloma, exciting agents generating excitement, and the role of minimal residual disease.

October 19, 2020

Elisavet Paplomata, MD, discusses the role of tucatinib ​in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

October 16, 2020

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

October 13, 2020

Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

October 12, 2020

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

October 07, 2020

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.

October 05, 2020

In our exclusive interview, O’Regan discusses the protocols the University of Wisconsin Carbone Cancer Center has put into place in light of COVID-19, the rise of telemedicine, best practices for in-person visits in the clinic, and the importance of maintaining well visits throughout the pandemic.

August 31, 2020

Ruth O’Regan, MD, discusses the utility of CDK4/6 inhibitors in breast cancer.

August 10, 2020

CDK4/6 inhibitors alone and/or in combination with HER2-directed therapies have been shown to elicit encouraging response rates and inhibit the growth of the cancer cells in HER2-positive breast cancer.

February 19, 2020

Ruth O’Regan, MD, shares her perspective on the use of biosimilars in breast cancer and their future in oncology.